DSGN
Design Therapeutics, Inc. [DSGN] Stock Forecast
Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000
DSGN Stock Summary
Top 10 Correlated ETFs
DSGN
Top 10 Correlated Stocks
DSGN
In the News
DSGN Financial details
Company Rating
Sell
Market Cap
206.65M
Income
-67.83M
Revenue
0
Book val./share
5.09
Cash/share
5.2
Dividend
-
Dividend %
-
Employees
57
Optionable
No
Shortable
Yes
Earnings
07 May 2024
P/E
-2.19
Forward P/E
-
PEG
-1.44
P/S
-
P/B
0.52
P/C
0.76
P/FCF
-2.42
Quick Ratio
23.58
Current Ratio
23.77
Debt / Equity
0.01
LT Debt / Equity
0.01
-
-
EPS (TTM)
-1.21
EPS next Y
-
EPS next Q
-
EPS this Y
-99.89%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-56.3%
Revenue last 5Y
-100%
Revenue Q/Q
-
EPS Q/Q
-22.22%
-
-
-
-
SMA20
33.33%
SMA50
100%
SMA100
100%
Inst Own
90.67%
Inst Trans
0.78%
ROA
-23%
ROE
-22%
ROC
-0.29%
Gross Margin
-
Oper. Margin
-
Profit Margin
-
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
1.94-8.47
52W High
-50.63%
52W Low
+295%
RSI
59
Rel Volume
1.38
Avg Volume
258.96K
Volume
357.55K
Perf Week
5.9%
Perf Month
33.9%
Perf Quarter
94.58%
Perf Half Y
81.19%
-
-
-
-
Beta
1.72
-
-
Volatility
0.09%, 0.53%
Prev Close
7.05%
Price
3.95
Change
6.76%
DSGN Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2023-12-31
| Metric | History | 2019-12-31 | 2020-12-31 | 2021-12-31 | 2022-12-31 | 2023-12-31 |
|---|---|---|---|---|---|---|
| 2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
| Revenue per share | 0 | 0 | 0 | 0 | 0 | |
| Net income per share | -0.08 | -0.15 | -0.77 | -1.05 | 0 | |
| Operating cash flow per share | -0.01 | -0.16 | -0.64 | -0.92 | 0 | |
| Free cash flow per share | -0.01 | -0.16 | -0.67 | -0.94 | 0 | |
| Cash per share | 0 | 0.67 | 8.36 | 5.93 | 0.01 | |
| Book value per share | -0.13 | -0.21 | 8.32 | 5.88 | 0 | |
| Tangible book value per share | -0.13 | -0.21 | 8.32 | 5.88 | 0 | |
| Share holders equity per share | -0.13 | -0.21 | 8.32 | 5.88 | 0 | |
| Interest debt per share | 0.03 | 0 | 0.08 | -0.02 | 0 | |
| Market cap | 1.13B | 2.23B | 983.49M | 571.56M | 148.36B | |
| Enterprise value | 1.13B | 2.23B | 688.56M | 548.75M | 148.34B | |
| P/E ratio | -551.17 | -269.67 | -27.68 | -9.75 | -2.22K | |
| Price to sales ratio | 1.35M | 9.88M | 0 | 0 | 0 | |
| POCF ratio | -8.12K | -257.57 | -33.48 | -11.14 | -2.53K | |
| PFCF ratio | -8.12K | -255.33 | -31.81 | -10.94 | -2.52K | |
| P/B Ratio | -309.79 | -197.34 | 2.57 | 1.75 | 534.27 | |
| PTB ratio | -309.79 | -197.34 | 2.57 | 1.75 | 534.27 | |
| EV to sales | 1.35M | 9.87M | 0 | 0 | 0 | |
| Enterprise value over EBITDA | -591.64 | -267.93 | -19.29 | -8.12 | -1.9K | |
| EV to operating cash flow | -8.12K | -257.3 | -23.44 | -10.69 | -2.53K | |
| EV to free cash flow | -8.12K | -255.06 | -22.27 | -10.51 | -2.52K | |
| Earnings yield | 0 | 0 | -0.04 | -0.1 | 0 | |
| Free cash flow yield | 0 | 0 | -0.03 | -0.09 | 0 | |
| Debt to equity | -0.19 | 0 | 0.01 | 0.01 | 0.01 | |
| Debt to assets | 7.72 | 0 | 0.01 | 0.01 | 0.01 | |
| Net debt to EBITDA | -0.32 | 0.29 | 8.26 | 0.34 | 0.24 | |
| Current ratio | 0.02 | 15.55 | 72.96 | 31.1 | 29.58 | |
| Interest coverage | 0 | 0 | 0 | 14.41 | 0 | |
| Income quality | 0.07 | 1.05 | 0.83 | 0.81 | 0.88 | |
| Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
| Payout ratio | 0 | 0 | 0 | 0 | 0 | |
| Sales general and administrative to revenue | 1.3K | 11.04K | 0 | 0 | 0 | |
| Research and developement to revenue | 1.98K | 26.81K | 0 | 0 | 0 | |
| Intangibles to total assets | 0 | 0 | 0 | 0 | 0 | |
| Capex to operating cash flow | 0 | 0.01 | 0.05 | 0.02 | 0 | |
| Capex to revenue | 0 | -336.28 | 0 | 0 | 0 | |
| Capex to depreciation | 0 | -15.2 | -11.92 | -2.26 | 0.05 | |
| Stock based compensation to revenue | 0 | 1.99K | 0 | 0 | 0 | |
| Graham number | 0.48 | 0.85 | 12.03 | 11.79 | 0.01 | |
| ROIC | 0.65 | 0.74 | -0.09 | -0.19 | -0.28 | |
| Return on tangible assets | -22.74 | -0.23 | -0.09 | -0.17 | -0.23 | |
| Graham Net | -0.13 | -0.22 | 8.19 | 5.69 | 0 | |
| Working capital | -3.64M | 33.9M | 380.15M | 324.34M | 274.96M | |
| Tangible asset value | -3.64M | -11.32M | 382.13M | 327.31M | 277.69M | |
| Net current asset value | -3.64M | -11.6M | 377.01M | 321.29M | 272.63M | |
| Invested capital | -0.19 | 0 | 0.01 | 0.01 | 0.01 | |
| Average receivables | 0 | 5K | 60K | 612.5K | 557.5K | |
| Average payables | 0 | 1.94M | 1.51M | 2.32M | 2.48M | |
| Average inventory | 0 | 53.5K | 680.5K | 69.5K | -557.5K | |
| Days sales outstanding | 0 | 16.15K | 0 | 0 | 0 | |
| Days payables outstanding | 547.06K | 102.13K | 4.58K | 2.37K | 0 | |
| Days of inventory on hand | 0 | 7.81K | 3.55K | -873.34 | 0 | |
| Receivables turnover | 0 | 0.02 | 0 | 0 | 0 | |
| Payables turnover | 0 | 0 | 0.08 | 0.15 | 0 | |
| Inventory turnover | 0 | 0.05 | 0.1 | -0.42 | 0 | |
| ROE | 0.56 | 0.73 | -0.09 | -0.18 | -0.24 | |
| Capex per share | 0 | 0 | -0.03 | -0.02 | 0 |
Quarterly Fundamentals Overview
Last date of statement is 2023-09-30 for Q3
| Metric | History | 2022-09-30 | 2022-12-31 | 2023-03-31 | 2023-06-30 | 2023-09-30 |
|---|---|---|---|---|---|---|
| 2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
| Revenue per share | 0 | 0 | 0 | 0 | 0 | |
| Net income per share | -0.29 | -0.27 | -0.3 | -0.36 | -0.28 | |
| Operating cash flow per share | -0.25 | -0.27 | -0.31 | -0.25 | -0.26 | |
| Free cash flow per share | -0.25 | -0.28 | -0.31 | -0.25 | -0.26 | |
| Cash per share | 6.17 | 5.91 | 5.64 | 5.42 | 5.2 | |
| Book value per share | 6.11 | 5.86 | 5.6 | 5.3 | 5.09 | |
| Tangible book value per share | 6.11 | 5.86 | 5.6 | 5.3 | 5.09 | |
| Share holders equity per share | 6.11 | 5.86 | 5.6 | 5.3 | 5.09 | |
| Interest debt per share | 0.04 | 0.03 | 0.06 | 0.06 | 0.06 | |
| Market cap | 932.68M | 573.17M | 322.59M | 352.48M | 132.13M | |
| Enterprise value | 894M | 550.36M | 296.66M | 328.66M | 107.41M | |
| P/E ratio | -14.38 | -9.45 | -4.76 | -4.42 | -2.09 | |
| Price to sales ratio | 0 | 0 | 0 | 0 | 0 | |
| POCF ratio | -67.1 | -37.98 | -18.51 | -25.53 | -9.09 | |
| PFCF ratio | -65.64 | -37.27 | -18.42 | -25.37 | -9.06 | |
| P/B Ratio | 2.74 | 1.75 | 1.03 | 1.19 | 0.46 | |
| PTB ratio | 2.74 | 1.75 | 1.03 | 1.19 | 0.46 | |
| EV to sales | 0 | 0 | 0 | 0 | 0 | |
| Enterprise value over EBITDA | -46.85 | -28.38 | -13.7 | -14.63 | -5.71 | |
| EV to operating cash flow | -64.32 | -36.47 | -17.03 | -23.81 | -7.39 | |
| EV to free cash flow | -62.92 | -35.79 | -16.94 | -23.66 | -7.36 | |
| Earnings yield | -0.02 | -0.03 | -0.05 | -0.06 | -0.12 | |
| Free cash flow yield | -0.02 | -0.03 | -0.05 | -0.04 | -0.11 | |
| Debt to equity | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | |
| Debt to assets | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | |
| Net debt to EBITDA | 2.03 | 1.18 | 1.2 | 1.06 | 1.31 | |
| Current ratio | 33.47 | 31.1 | 35.25 | 25.22 | 23.77 | |
| Interest coverage | 12.9 | 8.91 | 167.84 | 0 | 0 | |
| Income quality | 0.79 | 0.87 | 0.9 | 0.69 | 0.92 | |
| Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
| Payout ratio | 0 | 0 | 0 | 0 | 0 | |
| Sales general and administrative to revenue | 0 | 0 | 0 | 0 | 0 | |
| Research and developement to revenue | 0 | 0 | 0 | 0 | 0 | |
| Intangibles to total assets | 0 | 0 | 0 | 0 | 0 | |
| Capex to operating cash flow | 0.02 | 0.02 | 0 | 0.01 | 0 | |
| Capex to revenue | 0 | 0 | 0 | 0 | 0 | |
| Capex to depreciation | -2.87 | -2.32 | -0.67 | -0.67 | -0.39 | |
| Stock based compensation to revenue | 0 | 0 | 0 | 0 | 0 | |
| Graham number | 6.32 | 5.98 | 6.18 | 6.52 | 5.68 | |
| ROIC | -0.05 | -0.05 | -0.06 | -0.07 | -0.06 | |
| Return on tangible assets | -0.05 | -0.04 | -0.05 | -0.06 | -0.05 | |
| Graham Net | 5.94 | 5.67 | 5.43 | 5.16 | 4.94 | |
| Working capital | 338.08M | 324.34M | 309.89M | 293.91M | 282.15M | |
| Tangible asset value | 340.94M | 327.31M | 312.82M | 296.8M | 284.96M | |
| Net current asset value | 334.86M | 321.29M | 307.01M | 291.21M | 279.63M | |
| Invested capital | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | |
| Average receivables | 718.5K | 930.5K | 1.04M | 984K | 1.1M | |
| Average payables | 2.35M | 2.82M | 2.88M | 2.33M | 2.06M | |
| Average inventory | 709K | -557.5K | -1.04M | -984K | -1.1M | |
| Days sales outstanding | 0 | 0 | 0 | 0 | 0 | |
| Days payables outstanding | 1.93K | 2.02K | 1.78K | 1.21K | 1.45K | |
| Days of inventory on hand | 0 | -743.33 | -630.65 | -625.59 | -793.58 | |
| Receivables turnover | 0 | 0 | 0 | 0 | 0 | |
| Payables turnover | 0.05 | 0.04 | 0.05 | 0.07 | 0.06 | |
| Inventory turnover | 0 | -0.12 | -0.14 | -0.14 | -0.11 | |
| ROE | -0.05 | -0.05 | -0.05 | -0.07 | -0.06 | |
| Capex per share | -0.01 | -0.01 | 0 | 0 | 0 |
DSGN Frequently Asked Questions
What is Design Therapeutics, Inc. stock symbol ?
Design Therapeutics, Inc. is a US stock , located in Carlsbad of Ca and trading under the symbol DSGN
What is Design Therapeutics, Inc. stock quote today ?
Design Therapeutics, Inc. stock price is $3.95 today.
Is Design Therapeutics, Inc. stock public?
Yes, Design Therapeutics, Inc. is a publicly traded company.
Company Profile
- Volume Average 258.96K
- Market Capitalization 206.65M
- Employee 57
- CEO Mr. Pratik Shah Ph.D.
- Headquarters Carlsbad,CA,US
- IPO Date 2021-03-29
-
Website
https://www.designtx.com 
Design Therapeutics, Inc. a preclinical-stage biopharmaceutical company, engages in the development of therapies for the treatment of genetic diseases caused by nucleotide repeat expansions. The company's portfolio of products comprises Friedreich Ataxia, a monogenic, autosomal recessive, progressive multi-system disease that affects organ systems dependent on mitochondrial function, eventually leading to neurological, cardiac, and metabolic dysfunction; and Myotonic Dystrophy Type-1 (DM1), a dominantly-inherited, monogenic progressive neuromuscular disease affecting skeletal muscle, heart, brain, and other organs. It is also developing GeneTAC product candidate portfolio for the treatment of other nucleotide repeat expansion-driven monogenic diseases, such as Fragile X syndrome, spinocerebellar ataxias, amyotrophic lateral sclerosis, frontotemporal dementia, Huntington disease, and spinobulbar muscular atrophy. Design Therapeutics, Inc. was incorporated in 2017 and is headquartered in Carlsbad, California.
